WHITEHAWK THERAPEUTICS INC (WHWK) competitors & alternatives
Health Care · NASDAQ
WHITEHAWK THERAPEUTICS INC (WHWK)'s top competitors and alternatives — its most similar public companies — include Pfizer (PFE), Gilead Sciences (GILD), ADC THERAPEUTICS SA (ADCT), CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP), SUTRO BIOPHARMA INC (STRO), Exelixis (EXEL), ORIC PHARMACEUTICALS INC (ORIC), RELMADA THERAPEUTICS INC (RLMD), Revolution Medicines (RVMD), BridgeBio Oncology Therapeutics, Inc. (BBOT), ERASCA INC (ERAS) and AGENUS INC (AGEN). These are WHITEHAWK THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top WHWK competitors & alternatives
-
PfizerPFEHealth Care
Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular,…
$24.82 (as of 2026-07-22) · market cap $142.0B
-
Gilead SciencesGILDHealth Care
A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis,…
$130.34 (as of 2026-07-22) · market cap $163.6B
-
ADC THERAPEUTICS SAADCTHealth Care
ADC Therapeutics develops antibody-drug conjugates (ADCs) targeting hematologic and solid tumors, with its lead product ZYNLONTA commercialized for lymphoma.
$1.24 (as of 2026-07-22) · market cap $158M
-
CORBUS PHARMACEUTICALS HOLDINGS INCRBPHealth Care
Clinical-stage biopharmaceutical company developing next-generation antibody drug conjugates for oncology and a CB1 receptor inverse agonist for obesity.
$8.84 (as of 2026-07-22) · market cap $163M
-
SUTRO BIOPHARMA INCSTROHealth Care
Sutro Biopharma is a clinical-stage oncology firm using proprietary cell-free protein synthesis technology to develop specialized antibody-drug conjugates for…
$23.40 (as of 2026-07-22) · market cap $388M
-
ExelixisEXELHealth Care
Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline…
$54.98 (as of 2026-07-22) · market cap $14.0B
-
ORIC PHARMACEUTICALS INCORICHealth Care
ORIC Pharmaceuticals is a clinical-stage oncology company developing targeted therapies for hard-to-treat cancers through precision medicine approaches.
$10.75 (as of 2026-07-22) · market cap $1.1B
-
RELMADA THERAPEUTICS INCRLMDHealth Care
Clinical-stage biotech redirecting toward oncology and neurology with in-licensed chemotherapy delivery and neurosteroid platforms after terminating its lead…
$5.00 (as of 2026-07-22) · market cap $524M
-
Revolution MedicinesRVMDHealth Care
A precision oncology biotech in clinical development stages, pursuing targeted cancer therapies with no approved products yet but backed by substantial capital.
$183.03 (as of 2026-07-22) · market cap $39.0B
-
BridgeBio Oncology Therapeutics, Inc.BBOTHealth Care
BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including…
$8.90 (as of 2026-07-22) · market cap $701M
-
ERASCA INCERASHealth Care
A precision oncology company developing first-in-class RAS/MAPK pathway-targeting therapies for cancers driven by the most frequently mutated oncogene…
$19.51 (as of 2026-07-22) · market cap $6.8B
-
AGENUS INCAGENHealth Care
A clinical-stage immuno-oncology company advancing checkpoint immunotherapy and combination therapies, primarily botensilimab, while generating near-term…
$5.53 (as of 2026-07-22) · market cap $232M
Not quite? Describe exactly what you want →
Peers are WHITEHAWK THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: WHITEHAWK THERAPEUTICS INC (WHWK).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.